373360-53-3

Upstream product

• 373361-38-7 C₂₃H₂₆N₄O₅S 
• 373361-53-6 2-4-[2-(2-ethoxyethoxy)ethoxy]Phenylacetic Acid 
• 242459-77-4 2-[4-(2-[(benzyloxy)carbonyl]aminoethoxy)phenyl]Acetic Acid 

Downstream Products

• 373360-83-9 N-[5-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide 
• 373360-65-7 N-[5-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylethanethioamide 
• 373361-43-4 benzyl 5-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-3-[(2-phenylacetyl)amino]-1H-indazol-1-carboxylate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors

A novel series of 3,5-diaminoindazoles were prepared and found to be CDK inhibitors. Potent inhibitors against CDK1 and CDK2 were obtained by introduction of 1λ6-isothiazolidine-1,1-dioxide at 5-position of indazole. Anti-proliferative activities of compounds were evaluated using EJ, HCT116, SW620, and A549 cancer cell lines.

INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION

The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase (CDK). The present inventio